DEXCOM INC — Director's Dealing 2021

Mar 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-03-23

Reporting Person: DOUBLEDAY RICHARD (EVP Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-23	Common Stock	S	18	$352.88	Disposed	7745	Indirect
2021-03-23	Common Stock	S	74	$358.13	Disposed	7671	Indirect
2021-03-23	Common Stock	S	655	$360.3323	Disposed	7016	Indirect
2021-03-23	Common Stock	S	268	$361.3683	Disposed	6748	Indirect
2021-03-23	Common Stock	S	94	$362.45	Disposed	6654	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21554	Direct

Footnotes

F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.